Deals
Sanofi Will Pay Regeneron $1 Billion Upfront and Up to $8 Billion Total for Four Immunology Antibodies
The expansion of the partnership that produced Dupixent covers IL-13, IL-4, IL-4R-alpha and an IL-4xIL-13 bispecific, with development costs and profits split evenly.
AF
By Anna Ferreira
Oct 1, 2026 · 2 min read
Sanofi and Regeneron Pharmaceuticals said on Thursday they are expanding their long-running antibody alliance to add four next-generation long-acting immunology candidates, in a transaction worth up to $8 billion to Regeneron.
Discussion (0)
Sign in to join the discussion.
Loading comments…
AF
Anna Ferreira
Senior Correspondent, Corporate Strategy
Anna Ferreira writes for Corporate Insider Inc.